InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
79.75
(
0.00%
)
Bitcoin
67,645.07
(
-0.23%
)
Post# of 346133
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

tarvacin

Send PM Follow Ignore
Followers 3
Posts 191
Boards Moderated 0
Alias Born 04/19/2006

tarvacin

Re: None

Friday, 11/02/2007 2:36:07 PM

Friday, November 02, 2007 2:36:07 PM

Post# of 346133
Telaprevir Concerns

Also, The Phase IIb clinical trials had dropout rates of 18 percent and 12 percent in the telaprevir patients. Safety data showed the most common effects to be fatigue, rash, headache and nausea. Gastrointestinal disorders, rashes and anemia were higher than in the control arm of the study.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CDMO News
More CDMO News
InvestorsHub NewsWire

Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM

Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM

Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM

VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM

North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM

Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM

Start posting your company's news
Only $200 per official company press release!